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Abstract.  Cellular recognition and adhesion to the ex- 
tracellular matrix  (ECM) has a complex molecular ba- 
sis,  involving both integrins  and cell surface proteo- 
glycans (PG).  The current studies have used specific 
inhibitors of chondroitin  sulfate proteoglycan (CSPG) 
synthesis along with anti-a4  integrin  subunit mono- 
clonal antibodies to demonstrate that human melanoma 
cell adhesion to an A-chain derived, 33-kD carboxyl- 
terminal  heparin binding fragment of human plasma 
fibronectin (FN) involves both cell surface CSPG and 
o~4/~1 integrin.  A direct role for cell surface CSPG in 
mediating melanoma cell adhesion to this FN fragment 
was demonstrated by the identification of a cationic 
synthetic peptide, termed FN-C/H-III, within the frag- 
ment.  FN-C/H-III is located close to the amino termi- 
nal end of the fragment, representing residues #1721- 
1736 of intact FN.  FN-C/H-III binds CSPG directly, 
can inhibit CSPG binding to the fragment,  and pro- 
motes melanoma cell adhesion by a CSPG-dependent, 
ot4~l  integrin-independent  mechanism.  A  scrambled 
version of FN-C/H-III does not inhibit CSPG binding 
or cell adhesion to the fragment or to FN-C/H-III,  in- 
dicating that the primary sequence of FN-C/H-III is 
important  for its biological properties. 
Previous studies have identified three other synthetic 
peptides from within this  33-kD FN fragment that 
promote cell adhesion by an arginyl-glycyl-aspartic 
acid (RGD) independent mechanism.  Two of these 
synthetic peptides (FN-C/H-I and FN-C/H-II) bind 
heparin and promote cell adhesion,  implicating  cell 
surface PG in mediating cellular recognition of these 
two peptides.  Additionally, a  third  synthetic peptide, 
CS1,  is located in close proximity to FN-C/H-I and 
FN-C/H-II and it promotes cell adhesion by an a4/31 
integrin-dependent  mechanism.  In contrast to FN- 
C/H-III, cellular recognition of these three peptides 
involved contributions  from both CSPG and or4 inte- 
grin subunits.  Of particular  importance are observa- 
tions demonstrating that CSl-mediated melanoma cell 
adhesion could be inhibited by interfering  with CSPG 
synthesis or expression.  Since CS1 does not bind 
CSPG, the results suggest that CSPG may modify the 
function and/or activity of o~4~  1 integrin on the sur- 
face of human melanoma cells.  Together,  these results 
support a  model in which the PG and integrin binding 
sites within the 33-kD fragment may act in concert to 
focus these two cell adhesion receptors into close 
proximity on the cell surface, thereby influencing ini- 
tial cellular recognition events that contribute to mela- 
noma cell adhesion on this fragment. 
F 
mRONECTIN (FN)'  has  long  served as  a  prototype 
adhesion  molecule  with  which  to  understand  the 
molecular basis of cell adhesion.  Despite the evi- 
dence that has demonstrated a role for integrins in mediating 
cell adhesion  to FN (reviewed  in Hynes,  1987; Ruoslahti, 
1991; Albelda and Buck, 1990; Humphries, 1990; Springer, 
1990),  there is also evidence for an important role of cell 
surface proteoglycans  (PG) in mediating cell adhesion to FN 
(H66k et al.,  1984; Couchman and H66k,  1988; Saunders 
and  Bernfield,  1988;  Yamagata et  al.,  1989;  Gallagher, 
1.  Abbreviations  used  in  this paper:  ctDX,  p-nitrophenyl-c~-D-xyloside; 
/3DX, p-nitrophenyl-/3-1>xyloside;  CSPG,  chondroitin sulfate  proteogly- 
cans; EDC,  1-ethyl-3(3-dimethylaminopropyl)-carbodimide  hydrochloride; 
FN,  fibronectin;  GAG,  glycosaminoglycan;  NEM,  N-ethyl-maleimide; 
OVA, ovalbumin; PG, proteoglycans. 
1989). PG are complex macromolecules consisting of a core 
protein  to which highly  anionic  glycosaminoglycan  (GAG) 
chains are covalently attached by an O-linkage  to serine or 
threonine  residues on the core protein.  The anionic proper- 
ties of GAG on cell surface PG are important for the binding 
of many PG to their respective ligands  (H66k et al.,  1984; 
Couchman  and H66k,  1988; Gallagher,  1989). 
We have previously reported that a 33-kD heparin binding 
fragment,  which originates  from the carboxy terminal hepa- 
rin binding region of FN A-chains, is active at promoting the 
adhesion  and  spreading  of mouse melanoma  cells lines  in 
vitro (McCarthy et al., 1986, 1988a,  1990). This fragment, 
which inhibits lung colonization  of tumor ceils pretreated ex 
vivo before tail vein injection (McCarthy et al., 1988b), also 
promotes the adhesion  of various  other cell types such as 
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cells (Visser et al.,  1989),  and lymphocytes (Liao et al., 
1989; Wayner et al., 1989).  The heparin binding properties 
of this fragment make it a likely ligand for cell surface GAG 
and PG (Saunders and Bernfield, 1988). 
By the use of synthetic peptides (Humphries et al., 1987; 
McCarthy et al.,  1988a,  1990;  Haugen et al.,  1990),  cell 
adhesion to  the  33-kD  heparin  binding  fragment of FN 
A-chains  has been demonstrated to involve several  distinct 
sites.  Some of these synthetic peptides bind the GAG hepa- 
rin,  suggesting that they might promote cell adhesion by 
binding to cell surface GAG and PG. Specifically,  two syn- 
thetic peptides, termed FN-C/H-I (YEKPGSPPREVVPRP- 
RPGV) and FN-C/H-II (KNNQKSEPLIGRKKT), have pre- 
viously  been  shown  to  bind  heparin  and  promote  celt 
adhesion (McCarthy et al.,  1988a,  1990;  Haugen et al., 
1990).  Both FN-C/H-I and FN-C/H-II are located within 
type III repeat #14 of human plasma FN, which is near the 
carboxy-terminal end of the fragment. Another cell adhesion 
promoting  synthetic  peptide  from  within  this  fragment 
(Humphries et al., 1987), termed CS1 (DELPQLVTLPHPN- 
LHGPEILDVPST), is located within the alternatively spliced 
type IIICS domain (or V-region)  of FN that is contiguous 
with type III repeat #14 on FN A-chains. In contrast to FN- 
C/H-I and FN-C/H-II, CSI does not bind heparin (McCarthy 
et al.,  1990) and promotes cell adhesion by binding to the 
c~4~1 integrin receptor (Wayner et al., 1989; Mould et al., 
1990; Guan and Hynes, 1990).  Therefore, cell adhesion to 
the 33-kD heparin binding fragment of FN A-chains has a 
complex molecular basis, likely involving multiple cell ad- 
hesion promoting determinants that interact with both cell 
surface PG/GAG and c~4/31 integrin. 
In this study, we have further examined the molecular basis 
for the adhesion of highly metastatic human melanoma ceils, 
A375 SM (Fidler, 1986) to the 33-kD fragment of FN. As 
with many other human melanoma cell lines previously ex- 
amined (Bumol and Reisfeld, 1982;  Ross et al.,  1983;  re- 
viewed in Gallagher,  1989),  these cells express the over- 
whelming majority of their cell surface PG as chondroitin 
sulfate proteoglycan (CSPG). Through the use of specific in- 
hibitors of CSPG function, as well as specific anti-or4 integ- 
rin mAbs, we demonstrate that the adhesion of these mela- 
noma cells to the 33-kD  fragment involves  contributions 
from both u4-integrin subunits and cell surface CSPG. 
Furthermore, we have identified a novel heparin binding, 
cell adhesion-promoting synthetic peptide from within the 
33-kD fragment, termed FN-C/H-III (YRVRVTPKEKTG- 
PMKE). In contrast to the other three previously described 
cell adhesion promoting synthetic peptides from the 33-kD 
fragment, FN-C/H-III is located within type III repeat #12, 
representing residues #1721-1736  near the amino-terminal 
end of the fragment. Cell adhesion to FN-C/H-III was com- 
pletely resistant to anti-c~4 integrin mAbs, but sensitive to 
specific inhibitors of CSPG function, indicating that FN- 
C/H-HI  supports  melanoma  cell  adhesion  by  a  CSPG- 
dependent mechanism. In contrast, melanoma cell adhesion 
to the other three synthetic peptides was sensitive to anti-cr4 
integrin mAbs, and to a lesser extent, to CSPG inhibitors. 
The results suggest that these various cell adhesion promot- 
ing sites on this fragment act in a coordinated fashion to bind 
a  melanoma cell surface receptor complex,  consisting of 
CSPG and c~4B1 integrin, thereby influencing early cellular 
recognition events that contribute to cell adhesion on the 
fragment. 
Materials and Methods 
Cell Culture 
Highly metastatic human melanoma cells, A375SM,  which were selected 
by in vivo experimental metastasis assays of parent A375P cells in nude 
mice (Fidler,  1986) were kindly provided by Dr. I. J. Fidler (M.D.  Ander- 
son Hospital  Cancer Center,  Houston, TX). The cells were maintained in 
MEM supplemented  with 10% FCS, vitamin solution, and 1 mM sodium 
pyruvate. Cells were routinely used after less than 15 passages from frozen 
stocks to minimize phenotypic drift. 
Reagents 
BSA (fraction V, fatty acid free)  was purchased from Miles Laboratory 
(Elkhart, IN). Heparitinase, chondroitinase  ABC (protease free), and chon- 
droitinase ACII  were  purchased  from Seikagaku  America Inc.  (Bethes- 
da,  MD). p-Nitrophenyl-ct-o-xylopyranoside  (t~oX) was purchased from 
Koch-Light  Ltd.  (Suffole,  England).  1-ethyl-313-dimenthylaminopropyl)- 
carbodimide  hydrochloride  (EDC),  3-[3-Cholamidopropyl-dimethylam- 
monio]l-propanesulfate (CHAPS), p-nitrophenyl-/3-o-xylopyranoside (flDX), 
heparin (porcine  intestinal  mucosa,  grade I,  15  kD),  Sepharose  CL-4B, 
Sepharose  CL-6B,  DEAE-Sephacel,  CNBr-activated  Sepharose  CL-4B, 
N-ethyl-maleimide  (NEM), PMSE and EDTA were purchased from Sigma 
Chemical Co. (St. Louis, MO). FITC-goat anti-mouse IgG was purchased 
from Organon Teknika Corp.  (Durham, NC). 
mAbs 
mAbs against specific  integrin subunits  have been previously  described 
(Wayner et al.,  1988, 1989; Wayner and Kovach,  1992). These mAbs in- 
clude:  P4C2  and P4G9 (anti-et4-integrin),  PID6 (anti-~5 integrin), and 
P4CIO (anti-E1 integrin). 
Protein Isolation 
Human plasma FN was purified  as a by-product of factor VIII production 
by sequential ion exchange and gelatin affinity chromatography as described 
(McCarthy et al., 1986, 1988a). The tryptic/catheptic 33-kD heparin bind- 
ing fragment of FN A-chains was purified according to methods previously 
reported  (McCarthy et al.,  1988a). The 75-kD fragment was prepared by 
extensive trypsinization of FN followed by purification over sequential mAb 
180-8 affinity and Spherogel  TSK-3,000 columns as previously  described 
(McCarthy et al., 1986). Purity of FN, the 33-kD fragment, and the 75-kD 
fragment was verified by SDS-PAGE and Coomassie brilliant blue staining. 
Peptide Synthesis and Characterization 
Peptides  from FN were synthesized  at the Microchemical Facility  of the 
University of Minnesota (Minneapolis,  MN) using a peptide  synthesizer 
(system 990; Beckman Instruments, Inc., Palo Alto, CA). The procedures 
used were based on the Merrifield solid phase system as described previ- 
ously (Stewart and Young, 1984). Lyophilized crude peptides were purified 
by preparative reverse-phase HPLC on a C-18 column, using an elution gra- 
dient of 0-60% acetonitrile with 0.1% trifluoroacetic  acid in water. The pu- 
rity and composition of the peptides  were verified by HPLC analysis  of 
hydrolysates prepared by treating the peptides under nitrogen in 6 N HCI 
overnight at I10~  (McCarthy et al., 1990;  Haugen et al.,  1990; Skubitz 
et al.,  1990).  These peptides  included FN-C/H-I (YEKPGSPPREVVP- 
RPRPGV; representing residues  #1906-1924  of FN A-chains), FN-C/H-II 
(KNNQKSEPLIGRKKT;  residues  #1946-1960),  CS-1 (DELPQLVTL- 
PHPNLHGPEILDVPST;  residues #1961-1985),  FN-C/H-III (YRVRVTP- 
KEKTGPMKE;  residues #1721-1736), and scrambled FN-C/H-III (MKG- 
KVTREVRYPTKPE).  All  peptides  were  synthesized  with  a  tyrosine 
residue at the carboxy-terminal end to facilitate radioiodination of the pep- 
tides for certain analyses. 
Conjugation of the Peptides to Ovalbumin 
Synthetic peptides were chemically conjugated to ovalbumin (OVA) for all 
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pling of synthetic peptides to large carrier proteins results in enhanced hepa- 
rin binding activity and cell adhesion activities (Humphries et al.,  1987; 
McCarthy et al.,  1990;  Hangen et al.,  1990).  Briefly,  equal amounts (by 
weight) of the peptides and OVA were solubilized in water and mixed with 
a  10-fold  excess (by weight) of EDC dissolved in water.  The sample was 
then mixed overnight at 4~  on a  circular rotator.  The coupled peptides 
were then dialyzed extensively against PBS to remove the excess EDC and 
uncoupled peptide (Spectrapore 6,  10-kD exclusion; Spectrum Medical In- 
dustries, Los Angeles, CA). The molar ratio of each of the peptides to OVA 
was 5:1,  as determined by using a trace amount of radioactive peptides in 
the coupling reactions. The conjugates were stored at  -20~  until use. 
Determination of  Peptide Binding to Plastic Wells 
Each peptide was radiolabeled with 125Iodine (New England Nuclear, Bos- 
ton, MA) using an aqueous chloramine T reaction as described by Haugen 
et al. (1990). Plates were coated with the radiolabeled peptides, which had 
been coupled to OVA as described above,  for 24 h  at 37~  Plates were 
blocked with PBS/BSA (PBS containing 2  mg/ml BSA) for 3 h and then 
rinsed three times with the same buffer. Peptide remaining bound was solu- 
bilized with 0.5 N NaOH and 1% SDS, and bound radioactivity was quanti- 
tated in a Gamma Trac Gamma counter (TM Analytic, Elkgrove Village, 
IN). The amount of peptide bound was calculated based on the amount of 
radioactivity  recovered and the specific activity of the peptide/OVA con- 
jugates. 
Extraction of Cell Surface-associated Proteoglycans 
Cell surface PG were extracted from ceils radiolabeled with 35SO4 accord- 
ing to the methods described by Ross et al.  (1988).  Briefly, subconfluent 
cells were radiolabeled overnight with carrier-free Na235SO4 (sp ac 0.72 
Ci/mg;  New  England  Nuclear)  at  a  final  concentration  of 59  #Ci/ml. 
Monolayer cells were washed with cold serum-free MEM two times, and 
then cells were incubated for 30 rain at  18~  with MEM containing 50 
#g/ml  heparin  to  remove  weakly  associated  GAG  on  the  cell  surface 
(Yanagishita et al.,  1987).  Cells were harvested with  1 mM EDTA and 
washed three times with cold PBS. Cells (5  ￿  107 total) were incubated 
for 60 min at 4~  with 50 ml of extraction buffer that contained  10 mM 
Tris-HCl (pH 7.1),  0.9%  (vol/vol) NP-40, 2  mM EDTA, 0.25 mM DTT, 
1 mM NEM, and  1 mM PMSF with gentle shaking. The suspension was 
centrifuged at 2,000 rpm for  10 min to remove the insoluble cell debris. 
The supernatant was collected and then centrifuged at 10,000 rpm for 30 
min. One-fifth volume of RNase (Sigma Chemical Co.) was added to the 
supernatant and then incubated for 60 min at 37~  Crude PG were exten- 
sively dialyzed against "urea buffer" containing 6 M urea, 50 mM Tris-HCl 
(pH 7.0),  10 mM EDTA, 0.1 mM PMSE i mM NEM, and 10 mM 6-amino- 
caproic acid, and then separated on DEAE-Sephacel chromatography as de- 
scribed below. 
Anion-Exchange Column Chromatography of  PG 
DEAE-Sephacel beads (20-ml bed volume) were packed in a glass column 
equilibrated with the urea buffer. The crude PG were applied to the column 
and washed with three column volumes of the urea buffer to remove un- 
bound material. The bound material was eluted with a  linear gradient (0 
to 1 M) of NaCI in urea buffer, and 1-ml fractions were collected. The radio- 
active fractions were pooled, extensively dialyzed against water, and then 
lyophilized.  Recovery  of [35S]sulfate-labeled  macromolecules from this 
column was routinely >90%. 
Size Exclusion Column Chromatography 
Hydrodynamic properties of [35S]sulfate-labeled molecules were evaluated 
by size exclusion chromatography on 100  x  1 cm columns of Sepharose 
CL-4B equilibrated with  1% Triton X-100, 4 M  guanidine-hydrochloride, 
and 50 mM sodium acetate (pH 5.8).  The Vo and Vt of this column were 
determined as described previously (Klein et al.,  1986).  Separation was 
carried out at room temperature at a flow rate of 3 ml/h, and recovery from 
this column was >95 %. 
Generation of  Glycosaminoglycan Chains 
GAG were removed from the core protein by alkaline E-elimination (Klein 
et al.,  1986). Briefly, purified lyophilized PG were dissolved in water and 
incubated with 2  M  NaBI-L, and 0.05 M  NaOH (final concentrations) for 
24 h at 45~  The reaction was stopped by adding glacial acetic acid to a 
pH of 5 to 6. The reaction mixture was applied to a Sephadex G-50 column, 
equilibrated with 0.13  M  formic acid and 0.073  M  NI-IaOH to desalt the 
reaction and to ensure that the GAG were not non-specifically degraded by 
the treatment. Under these conditions, over 99% of applied GAG were re- 
covered from the Vo fractions. The Vo fractions were pooled, lyophilized, 
and further characterized for GAG type and hydrodynamic properties. 
Characterization of  GAG Chain 
To purify and evaluate the hydrodynamic properties of the alkaline borohy- 
dride  released  GAG,  the  samples were  applied  to  a  Sepharose  CL-6B 
column as described by Klein et al. (1986). Nitrous acid deaminative cleav- 
age was performed by first solubilizing GAG in 100 #1 of water, 500/zl of 
1 N HCI, and 500/zl of N-butyl nitrate (Sigma Chemical Co.). The reaction 
was carried out for 2 h at room temperature and was stopped by adding 500 
~1 of 1 N  NaOH.  The samples were frozen, lyophilized and applied to 
Sephadex G-50 columns, equilibrated with 0.13 M formic acid, and 0.073  M 
NHaOH.  Nitrous acid-resistant GAG, eluting in the Vo of the Sephadex 
G-50 columns, were then treated with 1 U of chondroitinase ABC or chon- 
droitinase ACII in 500/zl of 0.1  M  Tris-HC1 (pH 8.0) containing 0.03  M 
sodium acetate, 0.01 M EDTA, 0.01 M NEM, 0.01 M PMSF, and 0.36 mM 
pepstatin for 3 h at 37~  as described previously (Klein et al., 1986). After 
the enzyme treatment, samples were reapplied to a Sephadex G-50 column 
and analyzed for relative sensitivity to chondroitinase digestion.  Percent 
recovery from these columns was routinely >t95 %. 
Purification of  PG or GAG on Ligand Affinity Columns 
Synthetic peptides coupled to OVA, OVA/OVA, or the 33-kD fragment were 
coupled to CNBr-activated Sepharose 4B according to the methods recom- 
mended by the manufacturer. PG or GAG were dissolved in 20 mM Tris- 
HC1 (pH 6.8),  50 mM NaC1, 0.5% CHAPS,  1 mM CaCI2,  1 mM MgC12, 
1 mM PMSE and 1 mM NEM (column buffer), and then applied on OVA/ 
OVA conjugate beads (sham column) to remove PG or GAG that nonspe- 
cifically bind to the beads. The flow through fractions (>95%  of applied 
radioactivity) were collected and applied to the FN-C/H-III, CSI, or 33-kD 
fragment coupled  columns.  After  washing the columns with  30  ml  of 
column buffer, the bound radioactivity was eluted with a  linear gradient 
of NaCI. 
In some experiments, the purified PG were preincubated with FN-C/H- 
III/OVA,  scrambled FN-C/H-III/OVA, or OVA/OVA for 2 h at 4~  and then 
applied to a  33-kD fragment coupled column that had been equilibrated 
with  column  buffer  containing  FN-C/H-III/OVA,  scrambled  FN-C/H- 
III/OVA,  or OVA/OVA.  The bound radioactivity  was eluted as described 
above. 
Solid Phase pH]heparin Binding Assay 
Commercial [3H]heparin (0.5 mCi/mg sp ac; ICN Immunobiologicals, It- 
vine, CA) was purified by charge and size on HPLC-DEAE and Sepharose 
CL-6B columns as described previously (McCarthy et al., 1990). The abil- 
ity of various ligands to  bind purified  [3H]heparin was assessed with a 
solid-phase binding assay using polystyrene 96-well microtiter plates (Im- 
mulon I; Dynatech Laboratories Inc., Chantilly, VA) as a support, as previ- 
ously described (McCarthy et al.,  1988a,  1990).  The substrata were ad- 
sorbed with various ligands as for the cell adhesion assays described below. 
The plates  were then blocked with PBS/BSA,  washed, and  [3H]heparin 
was added to the wells in PBS/BSA containing 0.1%  CHAPS. The plates 
were then incubated for 2 h at 37~  at which time they were washed five 
times with PBS/BSA/CHAPS to  remove the unbound [3H]heparin.  The 
bound [3H]heparin was solubilized with 0.5 N NaOH containing 1% SDS, 
and quantitated using a liquid scintillation counter (model 3801;  Beckman 
Instruments). Specific binding of [3H]heparin was assessed by performing 
the binding in the presence of a  100-molar excess of unlabeled heparin. 
Generation and Purification of  Polyclonal Antibodies 
against FN-C/H-III 
Polyclonal antibodies against FN-C/H-III were generated according to the 
methods described by McCarthy et al. (1990). Briefly,  FN-C/H-III was cou- 
pled to keyhole limpet hemocyanin (KLH; Sigma Chemical Co.) using EDC 
as a coupling reagent as described above for coupling peptides to OVA. The 
conjugate was mixed with Freund's adjuvant and then used to immunize 
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by precipitation with ammonium sulfate followed by DEAE anion exchange 
chromatography as described previously (Skubitz et al.,  1988).  Purity of 
the IgG was determined by SDS-PAGE and Coomassie brilliant  blue stain- 
ing of the gels. Specificity of the purified IgG was then determined by 
ELISA as previously described (McCarthy et al.,  1990;  Hangen et ai., 
1990; Chelberg et al.,  1990). 
Cell Adhesion Assays 
Cell adhesion assays were performed as described previously with minor 
modifications (McCarthy et al., 1990; Chelberg et al., 1990; Haugen et al., 
1990).  Briefly,  purified  proteins or  the  peptide-OVA  conjugates were 
diluted to various concentrations in PBS, and 50-~1 aiiquots were dispensed 
into Immulon 1 polystyrene microtiter wells. The wells were incubated at 
37~  for 4 h, and nonspecitic sites on the plastic were then blocked by treat- 
ing the wells with 200 Itl of PBS/BSA. Subconfluent A375SM human mela- 
noma  cells  that  had  been  radiolabeled  overnight with  [3H]thymidine 
(3I-rI'dR, sp ac 6.7 Ci/mmol; New England Nuclear, Boston, MA), were 
harvested by rinsing with 1 mM EDTA, washed two times with MEM/BSA 
(MEM containing 2 ms/ml BSA and 0.15 mM Hepes, pH 7.2) and adjusted 
to a concentration of 10  s cells/m1 in the same medium. Aliquots of 100 #1 
of the cell suspension were dispensed into the wells and the cells were in- 
cubated at 37~  for various lengths of time, as indicated in the Results sec- 
tion. The assays were terminated by aspirating loosely bound and unbound 
cells from the wells,  washing the wells three times, and solubilizing  the 
bound cells in 0.5 N NaOH containing 1% SDS. Bound radioactivity, deter- 
mined in a liquid scintillation  counter (model 3801; Beckman Instruments), 
was used to calculate the percentage of cefts that remained adherent to each 
substratum relative to the total number of cells added to each well. Unless 
otherwise indicated, the data represent the means of triplicate determina- 
tions. 
Inhibition of  Cell Adhesion 
Plates were coated with the 33-kD fragment or peptideYOVA  conjugates at 
concentrations that promoted half maximal cell adhesion (4.2 pmole of the 
33-kD fragment, 20 nmole of FN-C/H-I, 20 nmole of FN-C/H-II,  100 
nmole of FN-C/H-III, or 80 nmole of CS1). The plates were then prein- 
cubated with various concentrations of polyclonal IgG against FN-C/H-III 
or purified normal rabbit IgG for 60 min at room temperature.  Radiolabeled 
cells were then incubated in the plates, in the continued presence of the IgG, 
for 30 min as previously described (McCarthy et al., 1990; Haugen et al., 
1990). 
Inhibition assays using [nAbs against specific integrin subunits were per- 
formed as previously described (Wayner et al., 1989; Wayner and Kovach, 
1992). Briefly, radiolabeled ceils were preincubated with the mAbs for 20 
vain at room temperature. The ceils were then added to wells precoated with 
half-maximal concentrations of peptides or proteins, and incubated for 30 
rain at 37~  The wefts were then washed and adherent cells were quanti- 
rated as for the cell adhesion assays, as described above. 
Chondroitinase ABC or  p-Nitrophenyl 
~-wxyloside Pretreatments 
Treatment of cells with chondroitinase ABC, to remove CS GAG from cell 
surface  CSPC~, was carried out before the cell adhesion assays based on 
the methods described by Sannders and Bernfield (1988). Briefly, melanoma 
cells radiolabaled with 3H-TdR were harvested, pelleted, and resuspended 
in MEM/BSA in the presence or absence of 0.5 U/ml of protease-free chon- 
droitinase ABC or heperitinase. The resuspended cells were then prein- 
cubated for 20 rain at 37~  prior to dispensing into the microtiter wefts. 
Chondroitinnse ABC or heparitinnse at 0.5 U/ml was included in the assay 
to prevent re-expression  of intact cell surface CSPGs or HSPGs, respec- 
tively, during the course of the 30-rain assay. 
As a second approach, melanoma cells were pretreated for 24 h with 
1 mM p-nitrophenyl 8vX to inhibit the expression of intact CSPG. aDX, 
an inactive analogue of ~I3X, was also used in a similar manner for some 
experiments as a negative control. ODX has been previously shown to inter- 
fere with CSPG synthesis by competing for gaiactosyl-transferase  I, result- 
ing in the uncoupling of CS GAG synthesis from that of CSPG (Schwartz, 
1977; Kato et ai., 1978; L~hmander et al., 1979). Cells were then harvested 
as described for the cell adhesion assay and adjusted to the appropriate con- 
centration in MEM/BSA containing 1 mM BDX or cwX to prevent re- 
expression of the CSPG during the course of the 30-rain assay. 
Flow Cytometry 
Cells were harvested with I mM EI31"A  and washed three times with MEM 
containing 2 rag/m1 BSA and 0.02% NAN3. Aliquots of 106 cells were in- 
cubated in 100 ~  of the same buffer including primary antibodies (final di- 
lution of 1:100) for 35 min at room temperature with tapping every 5 min. 
Cells were washed with the buffer three times and incubated in 100 ~1 of 
the buffer including FITC-goat anti-mouse IgG (final dilution of 1:250) for 
35 min at room temperature with tapping every 5 min. The titers of the pri- 
mary and secondary antibodies were maximized under these experimental 
conditions.  Cells were washed with the buffer three times, resnspended in 
200 #1 of the buffer, and then analyzed on a FACS Star (FACS is a registered 
trademark of Becton-Dickinson & Co., Mountain View, CA). 
Results 
A375SM Cells Express Predominantly Chondroitin 
Sulfate Proteoglycans 
We first isolated and partially characterized 35SO~-PG from 
human melanoma cells.  Others have demonstrated  (Bumol 
and Roisfeld,  1982; Ross et al., 1983; reviewed in Gailagher, 
1989) that many human melanoma cell  lines almost exclu- 
sively express CSPG on their surface.  To determine  if the 
A375SM  human melanoma ceils  used in our studies  are 
similar  in this  regard, 3sSO4-PG were detergent extracted, 
partially purified, and characterized as described in Materi- 
als and Methods. As an initial purification step, detergent ex- 
tracted 3sSO~-labeled macromolecules were purified by an- 
ion ex.change chromatography, eluting as a broad peak from 
DEAE columns at 0.45 M NaCI (Fig.  1 A). Fractions from 
the DEAE column containing ~sSO,-macromolecules  were 
pooled and subjected to dissociative size exclusion chroma- 
tography  on Sepharose CL-4B  columns (Fig.  1 B).  The 
3sSO~-macromolecules had a large hydrodynamic size, elut- 
ing in the Vo of these columns. Alkaline borohydride reduc- 
tion of the 3sSO,-macromolecules  pooled from the fractions 
of the Sepharose CL-4B column greatly  retarded their elu- 
tion from size exclusion columns, eluting at K,v of 0.6 from 
Sepharose CL-6B colunms (Fig.  1 C), which is what would 
be expected if the radioactive sulfate had been incorporated 
into O-linked GAG. The 35SO4-GAG were 95 % resistant to 
degradation by nitrous acid and 90-95 % sensitive to treat- 
ment with chondroitinase  ABC or chondroitinase  AC II (not 
shown), consistent with their identity  as CS. 
Human Melanoma Cell Adhesion to the 
33-kD Fragment Involves both CSPG and a4{$I 
Integrin-dependent Mechanisms 
We next evaluated the relative  contributions  of melanoma 
cell associated PG and the 0~4~tl integrin receptor in mediat- 
ing A375SM human melanoma cell adhesion to the 33-kD 
fragment of FN, since this fragment  can act as ligand  for 
both PG/GAG and ~4~1  integrin  (McCarthy  et al.,  1988, 
1990; Saunders et aL,  1988; Wayner et al.,  1989; Haugen 
et al., 1990; Mould et aL, 1990). To initially evaluate poten- 
tial contributions of cell surface PG in mediating melanoma 
cell adhesion, the cells  were pretreated with either  chow 
droitinase ABC or heparitinase to determine if removal of ei- 
ther ceil surface CS or HS could interfere with melanoma 
cell adhesion to this  fragment.  Chondroitinase  ABC pre- 
treatment of the melanoma cells caused a partial (55 %) inhi- 
bition  of melanoma cell adhesion to the 33-kD fragment, 
whereas  pretreatment  with  heparitinase  had  no  effect  on 
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F/gure L A375 SM human melanoma cells express predominantly 
CSPG. Cell cultures were metabolically labeled overnight in the 
presence of 50 #Ci/ml of pSS]sulfate and the cell layer was subse- 
quently harvested and dialyzed. (,4) The dialyzed extract was then 
applied to a DEAE-Sephacel column and eluted using a linear 
NaC1 gradient from 0.1 to 0.8 M as indicated (  ). The ra- 
dioactive fractions were then pooled (indicated by the bracket), dia- 
lyzed, and lyophilized. (B) The pooled fractions were applied to a 
Sepharose CL-4B column under dissociative conditions. The indi- 
melanoma cell adhesion. These results support our data that 
these human melanoma ceils express mainly CSPG (Fig. 1) 
and also indicate that cell surface CS  partially mediates 
melanoma cell adhesion to the 33-kD fragment of FN. 
As a further test of  the potential involvement  of  cell surface 
CS  in mediating melanoma cell adhesion, the cells were 
treated for 24 h with 1 mM/~DX, an inhibitor of CSPG syn- 
thesis (Schwartz, 1977; Kato et al., 1978; Lohrnander 1979; 
Robinson and Gospodarowicz, 1984). As was observed with 
chondroitinase ABC  pretreatment,  the  exposure  of these 
cells to 1 mM/3DX also caused a  significant ("~50%), but 
not complete, inhibition in melanoma cell adhesion to the 
33-kD fragment. The inactive analogue of/3DX, omX, had 
no effect on melanoma cell adhesion to the fragment. The 
inhibition of cell adhesion produced by these treatments was 
not due to cytotoxic effects of the chondroitinase ABC as as- 
sessed by trypan blue exclusion as well as by incorporation 
of 3H-TdR or [35S]methionine into cells after treatment with 
#DX or c<oX (not shown). 
To ensure that these treatments did not affect the cell sur- 
face expression of ot4/~l integrin, the treated cells were ex- 
amined in the presence of specific anti-or4 integrin or anti-/5'l 
mAbs by flow cytometry (Fig. 2). These experiments demon- 
strated that A375SM cells express both a4 and/31 integrin 
subunits, consistent with previous reports (Wayner et al., 
1989; Mould et al., 1990).  Importantly, cells pretreated for 
24 h with 1 mM ~DX (Fig. 2) or chondroitinase ABC (not 
shown) exhibit identical levels of <~4 and 81 integrin subtmits 
compared to untreated controls. These results indicate that 
the inhibition of  cell adhesion observed in the presence of  the 
CSPG antagonists was not due to removal of ~4~i integrin 
from the cell surface, thus further supporting the notion that 
cell surface CSPGs play a direct role in mediating human 
melanoma cell adhesion to the 33-kD fragment. 
As expected based on previous reports  (Wayner et al., 
1989; Mould et al,, 1990; Wayner and Kovach, 1992), mela- 
noma cell adhesion to the 33-kD fragment was also inhibited 
in a concentration dependent fashion by the addition of anti- 
c~4 integrin mAb (Fig.  3 A).  In contrast to the effects of 
CSPG antagonists on celt adhesion to this fragment, the inhi- 
bition observed in the presence of high levels of certain anti- 
c~4 integrin mAb (P4C2) was essentially complete (90%). 
However, another anti-or4 integrin mAb (P4G9) could only 
partially (50-60%)  inhibit melanoma cell adhesion to the 
33-kD fragment, even when high concentrations (1:25 dilu- 
tion of P4G9 ascites) of the mAb were tested (not shown). 
Anti-or5 integrin mAb (P1D6),  which completely inhibited 
melanoma cell adhesion to a tryptic 75-kD RGD-containing 
fragment of FN (not shown), had no effect on melanoma cell 
adhesion to the 33-kD fragment, even at the highest concen- 
tration tested (Fig.  3 A).  Similarly, anti-~l  integrin mAb 
(P4C10) could also inhibit melanoma cell adhesion to 33-kD 
fragment or to the RGD-containing 75-kD fragment (not 
shown). These results confirm previous reports (Wayner et 
cated fractions in brackets, including the Vo (I  ......  0, were 
collected, dialyzed, and lyophilized. (C) The pooled purified PG 
from the Sepharose CL-4B column were treated with alkaline boro- 
hydride and then desalted on a Sephadex G-50 column. The result- 
ing GAG were then applied to a Sepharose CL-6B column. 
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Figure 2. Inhibition of CSPG synthesis by flDX does not affect cell surface expression of a4fll integrin. Cultured melanoma cells were 
preincubated (or not) with 1 mM/~DX for 24 h as described in Materials and Methods. Cultured cells were then released using EDTA 
and incubated with anti-c~4 integrin mAb (P4C2), anti-/31 integrin mAb (P4C10), or normal mouse ascites (NMA) at final dilutions of 
1:100 for 30 rain at room temperature. Cells were washed three times, incubated with FITC goat anti-mouse IgG at a final dilution of 
1:250 for 30 rain at room temperature and then analyzed by flow cytometry. 
al.,  1989;  Mould et al.,  1990) and illustrate that specific 
integrin subunits are important for melanoma cell recogni- 
tion of the 33-kD fragment. 
The inhibitory effects of submaximal levels (1:625  dilu- 
tion)  of anti-a4  integrin mAb  (P4C2)  on  melanoma  cell 
adhesion to this fragment could be potentiated by pretreating 
melanoma  cells  with  chondroitinase  ABC  (Fig.  3  B)  or 
1 mM/~DX (not shown). Similar results were obtained when 
using  suboptimal  levels of another anti-a4  integrin mAb 
(P4G9; not shown). No such potentiation of inhibition was 
observed in the presence of anti-c~5 integrin mAb (Fig. 3 B) 
or normal mouse ascites (not shown), demonstrating that the 
chondroitinase ABC-mediated potentiation of anti-o~4 inte- 
grin subunit mAb was specific in nature. These results sug- 
gest that a4/~l integrin and cell surface CSPG play a closely 
coordinated role in mediating melanoma cell adhesion to the 
33-kD fragment; consistent with our hypothesis that cell ad- 
hesion to this fragment involves both e~4/~l integrin-depen- 
dent and cell surface PG-dependent mechanisms (Haugen et 
al.,  1990; McCarthy et al.,  1990). 
Synthetic Peptide FN-C/H-III Binds pH]heparin 
and Promotes Cell Adhesion 
We have previously used the properties of positive net charge 
and negative net hydropathy indices as selection criteria for 
synthesizing FN-C/H-I and FN-C/H-II,  two peptides that 
bind  GAG  and  promote cell  adhesion  (McCarthy  et al., 
1988, 1990; Haugen et al., 1990). Using these same criteria, 
we have synthesized a  novel peptide, termed FN-C/H-III, 
which is in type III repeat #12 of human plasma FN.  FN- 
C/H-III (YRVRVTPKEKTGPMKE) represents FN residues 
#1,721-1,736 and would be predicted to occur in all isoforms 
of FN identified to date (Kornblihtt et al., 1985). In contrast 
to FN-C/H-I, FN-C/H-II, and CS1, peptide FN-C/H-III is 
located near the amino-terminal end of the 33-kD fragment. 
FN-C/H-III is similar to FN-C/H-I and FN-C/H-II in that 
it is also cationic (net charge of +3) and relatively hydro- 
philic (net hydropathy index of -23.7). FN-C/H-III was cou- 
pled to OVA, adsorbed to microtiter wells (Haugen et al., 
1990; McCarthy et al.,  1990), and evaluated for the ability 
to bind [3H]heparin or promote melanoma cell adhesion. 
Purified [3H]heparin bound to substrata  coated with  10 
#M FN-C/H-III in a concentration-dependent, specific, and 
saturable manner, while negligible amounts of pH]heparin 
bound to OVA/OVA (not shown). FN-C/H-III also promoted 
melanoma cell adhesion in a concentration dependent man- 
ner (Fig. 4 A). Soluble FN-C/H-III inhibited cell adhesion 
to substrata coated with FN-C/H-III/OVA,  whereas OVA/ 
OVA  had no inhibitory effect on melanoma cell adhesion 
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Figure 3.  Melanoma cell adhesion to the 33-kD fragment of FN in- 
volves both c(4/91 integrin and cell surface CSPG.  (A) Microtiter 
wells were coated with 4.2 pmoles of the 33-kD fragment, which 
promoted  half-maximal  cell  adhesion,  and  then  blocked  with 
PBS/BSA as described in Materials and Methods. Cells were prein- 
cubated with serial dilutions  of anti-a4 integrin mAb (P4C2, o) or 
anti-c~5  integrin  subunit  mAb (P1D6, o) for 30 min at room temper- 
ature before the cell adhesion assay. (B) Cells were pretreated  with 
chondroitinase ABC and/or a  1:625 dilution of anti-c~4 integrin 
mAb (P4C2) or anti-(~5 integrin mAb (P1D6). In each experiment, 
the cell adhesion assays were carried out for 30 min in the continued 
presence of anti-integrin  subunit mAbs and/or chondroitinase ABC. 
The standard error of means (SEMs) were <5 % of mean values in 
each case. Data points represent the means of triplicate determina- 
tions. 
to FN-C/H-III  coated substrata (Fig.  4  B).  In addition,  a 
scrambled version of FN-C/H-III  (MKGKVTREVRYPTK- 
PEY), with the same amino acid composition, net hydropa- 
thy index,  and net charge as FN-C/H-III,  failed to inhibit 
melanoma  cell  adhesion  to  FN-C/H-III  coated  substrata 
(Fig. 4  B); suggesting that primary sequence, and not just 
net charge, is important for the cell adhesion promoting ac- 
tivity of FN-C/H-III. 
Soluble  FN-C/H-III/OVA  also  inhibited  melanoma  cell 
adhesion to the 33-kD fragment in a concentration depen- 
dent manner (Fig.  4  C).  As has been previously observed 
Figure 4.  FN-C/H-III represents  a novel cell adhesion promoting 
synthetic peptide from within the 33-kD fragment of FN. (A) Mi- 
crotiter wells were coated with the indicated amounts of FN-C/H- 
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Ill/OVA (o) or OVA/OVA (e) and evaluated for their ability to sup- 
port melanoma cell  adhesion in a 30-min assay as described in 
Materials and Methods. Alternatively, microtiter wells were coated 
with 100 nmoles ofFN-C/H-III  (B) or 4.2 pmotes of purified 33-kD 
fragment (C), and evaluated for their ability to support melanoma 
celt adhesion in the presence of various concentrations  of FN-C/H- 
Ill/OVA (o), scrambled FN-C/H-III/OVA (u), or OVA/OVA (o) as 
described in Materials  and Methods.  SEMs were <10%  of mean 
values in each case,  and each experimental point represents  the 
mean of triplicate values. 
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Melanoma Cell Adhesion to the Various Synthetic Peptides 
Relative Cell Adhesion:~ 
Concentration of IgG (t~g/ml) 
Substratum *  4  20  100 
FN-C/H-III  78w  72~  25~ 
FN-C/H-II  110  105  91 
FN-C/H-I  93  95  105 
CS1  85  95  91 
* Plates were coated with the peptides at concentrations that promoted half- 
maximal cell adhesion as described in Materials and Methods. 
IgG was diluted in MEM/BSA to the indicated concentrations  and incubated 
in the wells for 60 rain as described in Materials and Methods.  Cell adhesion 
assays were carded out for 30 rain as described in Materials and Methods.  Data 
is expressed as a percentage of the cells that adhered  in the absence  of IgG. 
Normal rabbit IgG did not affect cell adhesion, even at a concentration  of 500 
/~g/ml (not shown),  Data represent the mean of triplicate determinations, and 
SEMS  were <5 % of mean values in each case. 
w  P  <  0.001  from  values observed in the absence  of IgG (by Student's  two 
tailed t test), 
for these experiments using FN-C/H-I, FN-C/H-II, or CS1 
(Haugen et al.,  1990; McCarthy et al.,  1990), soluble FN- 
C/H-Ill-mediated inhibition of melanoma cell adhesion to 
the fragment was never complete, reaching levels of •50- 
60% at the highest concentrations tested. These results are 
consistent with the notion that the 33-kD fragment contains 
multiple  distinct  cell  adhesion  promoting  sites.  Further- 
more, OVA/OVA or scrambled FN-C/H-III/OVA were totally 
ineffective  at inhibiting melanoma cell adhesion to the 33-kD 
fragment, emphasizing the importance of the primary struc- 
ture of  FN-C/H-I/I in mediating melanoma cell adhesion, ei- 
ther as a synthetic peptide or when present in the context of 
the larger fragment. 
Polyclonal antibodies generated against peptide FN-C/H- 
III were next evaluated for their ability to inhibit melanoma 
cell adhesion to FN-C/H-III/OVA or the 33-kD fragment. By 
ELISA, the purified anti-FN-C/H-IU specifically recognized 
FN-C/H-III and the 33-kD heparin binding fragment of FN, 
but did not recognize substrata coated with the negative con- 
trol peptides FN-C/H-I,  FN-C/H-II, or CS1  (not shown). 
The anti-FN-C/H-III IgG specifically inhibited cell adhesion 
to substrata coated with peptide FN-C/H-III, yet did not in- 
hibit melanoma cell adhesion to substrata coated with the 
control peptides FN-C/H-I,  FN-C/H-II, or CS1  (Table I). 
Anti-FN-C/H-III IgG also inhibited melanoma cell adhesion 
to substrata coated with the 33-kD fragment (not shown). 
However, this effect was only partial (30-35%),  which is 
similar to results we have previously obtained using anti-FN- 
C/H-I or anti-FN-C/H-II IgG to inhibit cell adhesion to this 
fragment (McCarthy et al.,  1990;  Haugen et al.,  1990). 
These results demonstrate that FN-C/H-III is an active cell 
adhesion promoting site within the 33-kD fragment, and are 
consistent with the notion that FN-C/H-IlI represents one of 
several such active sites within the fragment. 
FN-C/H-III Promotes CelI Adhesion 
by a CSPG-de~ndent Mechanism 
To initially examine the potential contribution of cell surface 
CSPG to cell adhesion on FN-C/H-III, cells were pretreated 
with chondroitinase ABC, heparitinase, ~DX, or ~DX before 
cell adhesion assays. Cell adhesion to FN-C/H-III was in- 
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Figure 5. Peptide FN-C/H-III promotes melanoma cell adhesion by 
a CSPG-dependent, u4 integrin subunit-independent mechanism. 
(A) Microtiter  wells were coated with  100 moles of FN-C/H- 
III/OVA and evaluated for the ability to support melanoma cell 
adhesion following  pretreatment of  the cells with 1 mM BoX, 1 mM 
c~DX, chondroitinase ABC, or heparitinase. (B) Alternatively, mi- 
crotiter wells adsorbed with 100 nmoles of FN-C/H-III/OVA were 
evaluated for their ability to support melanoma cell adhesion in the 
presence of the indicated concentrations of anti-a4  integrin mAb 
(P4G9; o), or anti-a5 integrin mAb (P1D6; D). Data points repre- 
sent the mean of triplicate determinations and SEMs were <10% 
of mean values in all cases. 
hibited by treatment of the cells with chondroitinase ABC or 
BoX but not by heparitinase or t~DX (Fig. 5 A). In contrast, 
neutralizing anti-or4 integrin subunit mAb (P4C2 or P4G9), 
which can effectively inhibit melanoma cell adhesion to the 
33-kD fragment, did not inhibit cell adhesion to FN-C/H-III 
coated substrata (Fig. 5 B), indicating that melanoma cell 
adhesion to FN-C/H-III is CS dependent and ~4 integrin 
subunit independent. 
CSPG purified by sequential chromatography over DEAE 
and Sepharose CL-4B columns (Fig. 1 B) were evaluated for 
the ability to bind to FN-C/H-III affinity columns. Purified 
CSPG bound to FN-C/H-III affinity columns, and eluted at 
moderately high ionic strength (0.4 M NaCI; Fig. 6 A). Alka- 
line borohydride released CS (Fig.  1 C) also bound to the 
same affinity columns, but CS eluted at a lower ionic strength 
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Figure 6.  Peptide FN-C/H-III binds purified CSPG and alkaline- 
borohydride released CS from melanoma cells. (A) CSPG purified 
sequentially over DEAE and Sepharose CL-4B columns were ap- 
plied to FN-C/H-III/OVA affinity column as described in Materials 
and Methods, and eluted from the FN-C/H-III/OVA column using 
a 0.05 to 0.8 M NaC1 gradient (  ). (B) Alkaline borohy- 
hydride released CS, purified over the Sepharose CL-6B columns, 
were applied to an FN-C/H-III/OVA affinity column and eluted 
using the same conditions as in A. The recovery for each condition 
was >95 %. Nonspecific binding of the samples, as judged by the 
ability to interact with OVA/OVA sham affinity columns, was <5% 
of the total radioactivity applied under these conditions. 
(0.25 M  NaC1)  than the CSPG (Fig.  6 B). When purified 
CSPG was iodinated to radiolabel core proteins, digested 
with chondroitinase ABC, and then applied to FN-C/H-III 
affinity column, no radioactivity bound to the columns (not 
shown). These results indicate that FN-C/H-III binds to CS 
but not CSPG core proteins. This is consistent with the cell 
adhesion data in which removal of cell surface CS inhibits 
melanoma cell adhesion to FN-C/H-III. 
We next examined the ability of FN-C/H-III to inhibit the 
binding of CSPG to affinity columns containing the 33-kD 
fragment.  The purified CSPG was preincubated with FN- 
C/H-III/OVA, scrambled FN-C/H-III/OVA, or OVA/OVA at 
final concentrations of 500/~g/ml,  and then applied to the 
33-kD fragment affinity column as described in Materials 
and  Methods.  Under these  experimental conditions,  FN- 
C/H-III almost totally prevented the binding of CSPG to the 
Table II. Binding of Purified CSPG to a 33-kD 
Fragment Affinity Column in the Presence of FN-C/H-III 
or Scrambled FN-C/H-III 
Pretreatment*  Flow through$  Bounds 
(dpm)  (dpm) 
Buffer  <50  6,982 
FN-C/H-III/OVA  6,850  100 
Scrambled FN-C/H-III/OVA  150  6,580 
OVA/OVA  123  6,745 
* The purified CSPG (,',,7,000 dpm) was preincubated with or without inhibi- 
tors (final concentrations of 500 tzg/ml) for 2 h at 4~  and then applied to the 
33-kD fragment at~nity column that had been equilibrated with the buffer con- 
taining the corresponding  inhibitors  at concentrations  of 500 ttg/ml. 
~: Columns  were  washed  with 6  ml  of the buffer  (Flow through) and  then 
bound material was eluted with 6 ml of buffer containing 0.2 M NaCI (Bound). 
33-kD fragment affinity column (Table II). In contrast, nei- 
ther scrambled FN-C/H-III/OVA nor OVA/OVA affected the 
binding of CSPG to the 33-kD fragment affinity column (Ta- 
ble II).  These results indicate that FN-C/H-III serves as a 
CSPG binding site in the context of the 33-kD fragment, and 
that the specific binding of FN-C/H-III to CSPG is related 
to the primary sequence of the synthetic peptide. 
Melanoma Cell Adhesion to FN-C/H-I, 
FN-C/H-H, and CS1 Differs from FN-C/H-III 
in Sensitivity to CSPG Antagonists and Neutralizing 
Anti-a4 Integrin mAb 
As a comparison to the FN-C/H-III cell adhesion data, we 
also evaluated the ability of the three previously described 
synthetic peptides, FN-C/H-I, FN-C/H-II, and CS1 to bind 
CSPG or to promote melanoma cell adhesion in the presence 
of CSPG antagonists and anti-cz4 integrin mAb. As might be 
expected from their  cationic properties,  affinity columns 
containing FN-C/H-I and FN-C/H-II bound purified CSPG 
(Fig.  7, A and B), however the concentration of NaC1 re- 
quired to elute the CSPG from these columns ('~0.2-0.25 M) 
was approximately half that required to elute the CSPG from 
the FN-C/H-III affinity column. In sharp contrast, affinity 
columns containing CS1 failed to bind the CSPG (Fig. 7 C). 
Melanoma cell adhesion to FN-C/H-I,  FN-C/H-II,  and 
CS1 was also evaluated following treatment of the cells with 
chondroitinase ABC or/3DX (Table III). In contrast to FN- 
C/H-III, cell adhesion to FN-C/H-II-coated substrata was 
only partially (•50%)  inhibited by chondroitinase ABC or 
j3oX, and cell adhesion to FN-C/H-I was even less affected 
(~15%  inhibition). Of particular interest was the observa- 
tion  that  these  treatments  also  significantly  (*50%)  in- 
hibited melanoma cell adhesion to the CSPG non-binding, 
a4/31  integrin-binding  synthetic peptide CS1.  As  was  ob- 
served for the 33-kD fragment, cell adhesion to all three syn- 
thetic peptides was resistant to treatment with heparitinase 
(Table III), or ctDX (not shown). 
We also tested the ability of anti-or4 integrin mAb to in- 
hibit melanoma cell adhesion to substrata coated with the 
three synthetic peptides (Fig. 8). As expected (Wayner et al., 
1989),  melanoma  cell  adhesion  to  CSl-coated  substrata 
could be completely inhibited by the addition of P4G9 anti- 
or4 integrin mAb  (Fig.  8 A).  Importantly, melanoma cell 
adhesion to FN-C/H-I or FN-C/H-II coated substrata could 
also be inhibited by pretreatment of these cells with P4G9 
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Figure 7.  Peptides FN-C/H-I  and FN-C/H-II,  but not CS1, bind 
purified melanoma cell  CSPG.  Affinity columns  containing  (A) 
FN-C/H-I/OVA, (B) FN-C/H-II/OVA, or (C) CS1/OVA were evalu- 
ated for their ability to bind purified CSPG from melanoma cells. 
The purified CSPG was applied to these affinity columns in buffer 
containing 0.05 M NaCl as described in Materials and Methods. 
The columns were then eluted with a 0.05 to 0.8 M gradient of NaCI 
(  )￿9 The recovery from each affinity column was 95 %. 
Nonspecific binding of the CSPG samples, as judged by their ability 
to bind to OVA/OVA sham affinity columns,  was less than 5 % of 
the total radioactivity applied under these conditions￿9 
Table II1. Effect of  Removal of Cell Surface CS 
Glycosaminoglycans  on Cell Adhesion to the Various 
Synthetic Peptides 
Relative cell adhesion in the presence of ir~ibitors$ 
Substratum*  /3DX  Cbondroitinase ABC  Heparitinase 
(%) 
FN-C/H-H  45w  43w  96 
FN-C/H-I  86  85  98 
CS1  50w  53w  97 
* Plates  were coated  with the  various ligands at concentrations which pro- 
rooted half-maximal cell adhesion. 
$ Cells  were pretreated with  1  raM /3DX  overnight,  or with chondroitinase 
ABC  or heparitinase in  PBS  containing  1.25  mM  CaCl2  for 20  min.  Cell 
adhesion assays were carded out in the continued presence of the various inhi- 
bitors.  Percent of inhibition was calculated compared to non-treated group. 
Data were calculated from the means of triplicate determinations and SEMs 
were <10%  of mean values in each case. 
w P  <  0.001 from values observed in the absence of the inhibitors (by Student's 
two tailed t  test). 
anti-tx4 integrin mAb (Fig. 8, B and C). P4C2, another anti- 
ct4 integrin mAb, could also inhibit melanoma cell adhesion 
to these three synthetic peptides, although the level of inhibi- 
tion was somewhat less (50-60%) than that observed with 
P4G9 (not shown). As controls, anti-or5 integrin mAb (Fig. 
8) or normal mouse ascites (not shown) did not inhibit mela- 
noma cell adhesion to these synthetic peptides, demonstrat- 
ing that the inhibitory effects of anti-c~4 integrin mAb on cell 
adhesion to these  three synthetic peptides  was  specific  in 
nature. 
Discussion 
Recent studies suggest that cellular recognition of the ECM 
may involve the coordinated action of distinct receptors on 
cell surfaces that interact with an array of closely spaced rec- 
ognition sites on insoluble ECM components. Early work on 
FN demonstrated that both RGD-containing domains and 
heparin binding domains within intact FN are required for 
focal  contact and focal adhesion formation in certain cell 
types (Lark et al., 1985; Woods et al., 1986). More recently, 
it has been reported that intracellular phosphorylation events, 
which immediately follow initial cell recognition of FN, ap- 
pear to involve both GAG-binding and integrin-binding do- 
mains (Guan et al.,  1991). These reports, as well as others 
(Kornherg et al.,  1991) suggest that the clustering of ECM 
cell surface receptors may be responsible, in part, for trans- 
mitting distinct signals to the interior of the cells, similar to 
the way in which lymphocytes use receptor clusters to recog- 
nize and respond to various target cells (reviewed in Springer, 
1990).  The current  studies,  which use  synthetic peptides 
from a FN fragment that has both integrin and PG-binding 
properties,  add further support to this generalized mecha- 
nism for cellular recognition of the ECM. 
By using  specific  inhibitors of CSPG  or o~4/~1 integrin 
subunit function, human melanoma cell adhesion to the 33- 
kD fragment of FN was shown to involve the activities of 
both types of cell surface adhesion receptors.  As expected, 
cell  adhesion to the 33-kD  fragment was  inhibited in the 
presence of anti-or4 integrin or anti-/~l integrin mAbs, but 
not in the presence of anti-a5 integrin mAbs.  Pretreatment 
of melanoma cells with either proteinase-free chondroitinase 
ABC (to enzymatically remove cell surface CS) or/~DX (tO 
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Figure 8. Melanoma cell adhesion to peptides FN-C/H-I, FN-C/H- 
II, and CS1 is sensitive to the inhibitory effects of anti-t~4 integrin 
subunit mAb. Microtiter wells were coated with (A) CS1/OVA, (B) 
FN-C/H-I/OVA, or  (C)  FN-C/H-II/OVA at  concentrations  that 
promoted  half-maximal  cell  adhesion,  and  then  blocked  with 
interfere with cell surface CSPG production) also caused 
significant (50%) inhibition of melanoma cell adhesion to 
the  33-kD  fragment.  The inhibition  of cell adhesion ob- 
served in the presence of these antagonists of CSPG function 
was not due to a loss of cell surface o~4 or/31 integrin subunits 
from the cell surface, as shown by flow cytometry; suggest- 
ing that CSPG might bind to and play a direct role in mela- 
noma cell adhesion to  the  33-kD  fragment.  Importantly, 
pretreatment of melanoma cells with either ~DX or chon- 
droitinase ABC could potentiate the inhibitory effect of sub- 
optimal levels of anti-a4 integrin mAb, which is consistent 
with an involvement of both cell surface CSPG and tx4 inte- 
grin subunits in mediating the initial recognition and adhe- 
sion of melanoma cells to the 33-kD fragment. Since certain 
anti-or4  and anti-ill  integrin mAbs  can completely inhibit 
melanoma cell adhesion to the 33-kD fragment and antago- 
nists of CSPG are only partially effective, it would appear 
that the c~4~1 integrin complex is fundamentally important 
for supporting adhesion on the 33-kD fragment. In contrast, 
cell surface CSPGs, in the absence of functional ct4fll inte- 
grin, may not be as efficient in promoting adhesion to the 
fragment. Such differences may relate to the relative affini- 
ties of each receptor for recognition sites within the frag- 
ment, or may be a reflection of specific differences in intra- 
cellular signals transmitted by each type of receptor. 
Evidence for the role of cell surface CSPG in promoting 
melanoma cell adhesion to the 33-kD fragment comes from 
the  identification  of  FN-C/H-III,  a  novel  cell  adhesion 
promoting synthetic peptide contained within type HI repeat 
#12 of FN, located near the amino terminus of the 33-kD 
fragment (McCarthy et al.,  1988). As with FN-C/H-I and 
FN-C/H-II (two other previously  identified cell adhesion 
promoting  synthetic peptides  from within  this  fragment), 
peptide FN-C/H-III is cationic, binds [aH]heparin, and pro- 
motes melanoma cell adhesion in a concentration-dependent 
fashion.  Both  soluble  FN-C/H-III/OVA  and  specific anti- 
FN-C/H-III IgG partially inhibited melanoma cell adhesion 
to the 33-kD fragment. These results are similar to those ob- 
tained using the same strategies to evaluate FN-C/H-I and 
FN-C/H-II (McCarthy et al.,  1990; Haugen et al.,  1990), 
and are consistent with the notion that the 33-kD fragment 
contains multiple distinct cell adhesion promoting sites. 
FN-C/H-III is also a major CSPG binding site within the 
33-kD fragment, as evidenced from the binding of CSPG (or 
alkaline reduced CS) to FN-C/H-III affinity columns, as well 
as by the ability of soluble FN-C/H-III to completely inhibit 
CSPG  binding  to  affinity columns  containing  the  33-kD 
fragment. Furthermore, based on specific inhibition studies, 
the cell adhesion promoting activity of FN-C/H-III is depen- 
dent on cell surface CS, and independent of  cell surface c~4~  1 
integrin. While soluble FN-C/H-III completely inhibits the 
binding of CSPG to the 33-kD fragment, it only partially 
inhibits cell adhesion to the fragment, consistent with the 
notion that PG-independent, ct4fll integrin-dependent adhe- 
PBS/BSA. Cells  were preincubated  with anti-or4 integrin mAb 
(P4G9, o), or anti-~t5 integrin mAb (P1D6, t3) for 30 min at 37~ 
and then evaluated for their ability to adhere to the various peptide 
coated substrata in the continued presence of the mAbs. The assays 
were performed for 30 rain,  and each data point represents the 
mean of triplicate determinations. The SEM were <10% of mean 
values in each case. 
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ognition of the fragment (Wayner et al.,  1989; McCarthy et 
al., 1990; Mould et al., 1990; Haugen et al., 1990). Impor- 
tantly, the primary sequence of FN-C/H-III is important for 
its biological activities,  as demonstrated by the  failure of 
scrambled FN-C/H-III, with the same amino acid composi- 
tion, net hydropathy, and net charge as the parent peptide 
FN-C/H-III,  to  inhibit  CSPG  binding  or  melanoma  cell 
adhesion to FN-C/H-III or to the 33-kD fragment. 
Melanoma cell adhesion to the other three cell adhesion 
promoting synthetic peptides,  FN-C/H-I,  FN-C/H-II, and 
CS1, was distinct from, and molecularly more complex than 
FN-C/H-III-mediated cell adhesion, in that cell adhesion to 
these three peptides was sensitive to anti-or4 integrin mAbs. 
Furthermore, inhibition of CSPG production or expression 
had differential effects on melanoma cell adhesion to these 
three  synthetic peptides.  Cell  adhesion to  FN-C/H-I was 
only slightly (15%) sensitive, whereas peptide FN-C/H-II- 
mediated adhesion  was  inhibited by  ,v50%.  Importantly, 
CSl-mediated melanoma cell adhesion was  also  inhibited 
50% by chondroitinase ABC or BoX pretreatments, despite 
the fact that the level of cell surface ct4B1 integrin is not al- 
tered by these treatments and CS1  does not directly bind 
purified CSPG. This inhibition was not due to nonspecific 
toxic side effects of antagonists of CSPG function, as sup- 
ported by trypan blue exclusion data, protein synthesis and 
3H-TdR incorporation analysis, as well as by the relative in- 
ability of either chondroitinase ABC or BoX to inhibit mela- 
noma cell adhesion on FN-C/H-I. While the exact mecha- 
nism by which melanoma cell surface CSPG can modulate 
cell adhesion to CS1 remains to be determined, one possibil- 
ity is that the CSPG may be important for modulating the 
affinity of ct4B1 integrin for specific ligands. Alternatively, 
it is possible that the CSPG may influence ct4Bl integrin in 
some other way, perhaps by altering intracellular signals that 
could change the functional capacity of ct4BI  integrin to 
mediate cell adhesion. 
While CS1 has clearly been shown by several investigators 
to bind c~4B1 integrin directly (Mould, 1990; Guan, 1990), 
additional  studies are required before definitive ligand-re- 
ceptor relationships can be established for FN-C/H-I and 
FN-C/H-II. Although the current studies demonstrate that 
FN-C/H-I and FN-C/H-II affinity columns can directly bind 
purified CSPG from melanoma cells, this binding is of some- 
what lower affinity than that observed for FN-C/H-III. Fur- 
thermore, inhibition of CSPG expression only partially in- 
hibits  melanoma  cell  adhesion  on  these  two  synthetic 
peptides, suggesting that FN-C/H-I or FN-C/H-II might in- 
teract with o~4 (or B1) integrin subunits, or possibly that these 
two synthetic peptides may be capable of binding both CSPG 
and u4B1 integrin. 
Regardless of the exact mechanism(s) involved, the results 
suggest a working model for A375 SM human melanoma cell 
recognition of the 33-kD fragment from FN A-chains (Fig. 
9). This model depicts two overlapping elements in the con- 
text of a larger cellular recognition domain within the 33-kD 
fragment, one of which is CSPG dependent, and a second 
which is t~4 integrin subunit dependent. According to this 
model, the CSPG-dependent element contains at least four 
sites,  characterized by  FN-C/H-III,  FN-C/H-I,  and  FN- 
C/H-II,  CS-1,  and  possibly  others  (Bober-Barkalow  and 
Schwarzbauer, 1991), all of  which could directly bind CSPG 
Cell 
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Figure  9.  Schematic diagram  illustrating a coordinated role for 
CSPG-dependent and c~4/31 integrin-dependent cellular recognition 
sites in mediating melanoma cell adhesion to the 33-kD fragment. 
Schematically depicted is a human melanoma cell initially recog- 
nizing substrata coated with the 33-kD fragment of human plasma 
FN-A-chains. The three type III repeating homologies (12, 13, and 
14) and a portion of the type IIICS insert are depicted, as are the 
relative locations of the four synthetic peptides used in this study. 
According  to this model, the proximity of  the CSPG-dependent and 
c~4~/1-integrin-dependent  elements, within the context of a larger 
cellular recognition domain within this fragment, would act to fo- 
cus cell surface CSPG and ot4/31 integrin on the ventral surface of 
the plasma membrane.  This clustering of cell surface receptors 
would act to modulate early cellular events that contribute to mela- 
noma cell adhesion on this fragment. Evidence for this model is 
summarized in the Discussion. 
and/or be influenced by cell surface CSPG.  Additionally, 
there is a  multisite cr  integrin-dependent element within 
this  larger domain,  consisting of at least FN-C/H-I,  FN- 
C/H-II, and CS1, and possibly other sites within the frag- 
ment (Mould and Humphries,  1991). The potential signifi- 
cance of the overlapping nature of  these two elements is that 
each could act in concert to efficiently bring cell surface 
CSPG and a4B1 integrin into close proximity during initial 
melanoma cell recognition of the 33-kD fragment. Ligand- 
induced clustering of cell surface ECM  receptors on the 
plasma membrane could have a profound effect on altering 
the conformation and binding specificity of receptors within 
such clusters or it could influence the generation of intracel- 
lular signals  that follow initial cellular recognition of the 
33-kD fragment, thereby affecting cell adhesion, cytoskele- 
tal reorganization, cell motility, and other diverse aspects of 
cell phenotype. 
Although  there is  evidence suggesting that  CSPG  (and 
specifically CS GAG) is associated with cellular de-adhe- 
sion, the current studies argue that this may not be a univer- 
sal property of all CSPG. Much of the data describing the 
ability of CSPG to weaken cell adhesion rely on cell adhe- 
sion assays in which CSPG from a variety of sources is used 
to compete for cell adhesion to substrata coated with various 
ligands (e.g., FN). These approaches have led to the hypoth- 
esis  that  exogenous CSPG  may weaken cell  adhesion  by 
binding to ECM components and masking other cell adhe- 
sion promoting sites (e.g., RGD) within these ECM compo- 
nents (reviewed in Ruoslahti, 1988; Gallagher, 1989). How- 
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that cell surface CSPG is enriched on cell surface micro- 
spikes (Garrigues et al.,  1986),  suggesting that cell surface 
CSPG may also play a role in mediating early recognition 
events in cell adhesion. The current studies are consistent 
with the latter hypothesis. While we cannot currently explain 
the discrepancies between these two apparently disparate no- 
tions, one possibility is that the biological activity of cell sur- 
face CSPG may depend on the nature, function, and intracel- 
lular signals transmitted by cell surface CSPG core proteins. 
More definitive identification of the CSPG core protein(s) 
produced by these human melanoma cells will be required 
to test this hypothesis directly. 
Implicit in this more generalized "receptor cluster" model 
of ECM recognition is the prediction that information trans- 
mitted into the cell is closely related to the specific combina- 
tions of cell surface receptors that may come into proximity 
on the cell surface as a  result of the influence of closely 
spaced cellular recognition domains within the ECM. Cell 
type-specific differences in ECM receptor expression could 
therefore  alter  the  molecular  composition  of such  com- 
plexes, resulting in profound differences in cell type-specific 
signals transmitted by the ECM. Changes that occur in the 
composition of these receptor complexes (e.g., presence or 
absence of specific integrins, type of PG core protein, etc.) 
as a function of malignant progression could be fundamen- 
tally  important  in  generating  aberrant  signals  that  may 
modulate tumor cell invasion and metastasis. Future work on 
this model in the area of tumor cell biology should include 
a  comparison of tumor cells at various stages of progres- 
sion. Such studies may help in the understanding of the biol- 
ogy of ECM mediated-tumor cell adhesion, invasion, and 
metastasis. 
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